An announcement from Innovent Biologics ( ($HK:1801) ) is now available. Innovent Biologics has announced the approval of SYCUME®, China’s first ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new ...

Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian ...

VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Complementing its antibody offerings, BosterBio provides a range of ELISA kits designed for quantitative detection of proteins, cytokines, and other biomarkers. These kits are widely used in drug ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...